Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Takeda is a large drug company that discovers, makes, and sells medicines for rare diseases, cancer, the immune system, the brain, and the gut.
Takeda is one of the world's big pharmaceutical companies — a Japanese giant that turns science into prescription drugs. Its medicines treat rare genetic disorders, cancers, inflammatory and immune conditions, brain diseases like narcolepsy, and digestive problems. It also runs a vaccines business and sells some older products in Japan. You don't buy Takeda's stuff yourself at a pharmacy shelf. Doctors prescribe it, hospitals and insurers pay for it, and governments decide whether to cover it.
The core money engine is simple: Takeda invents or buys a drug, wins approval from regulators, then sells it for years while it is protected by patents. The best sellers are often "specialty" drugs — treatments for rare diseases that cost a lot per patient but serve small groups of people. Its biggest recent blockbusters include Entyvio for inflammatory bowel disease, Vyvanse for ADHD, and a growing lineup of rare-disease and plasma-based therapies. That mix matters because rare-disease drugs face less competition and can command premium prices, but they also depend on a handful of products staying strong. Takeda's big turning point was buying Shire in 2019 for about $59 billion. That deal doubled its size and pushed it hard into rare diseases and plasma therapies, but it also loaded the company with debt. Since then management has been selling off non-core assets — things like consumer health and some older medicines — to pay that debt down and focus on the highest-value areas. By its fiscal 2024 results, the company was still working through that plan. The risk is real: patents on key drugs eventually expire, and cheaper copies eat the sales. Takeda has had to keep refilling the pipeline with new drugs while managing a heavy debt load.
In 1781, a 32-year-old named Chobei Takeda opened a small shop in Doshomachi, Osaka, the heart of Japan's medicine trade. He didn't make anything himself. He bought medicines from wholesalers, split them into smaller batches, and sold them to local merchants and doctors. That humble reselling business was the seed of the company we know today as Takeda.
For over a century, Takeda was a pure broker, buying and reselling other people's medicines. That changed in 1895, when it bought a drug factory in Osaka and started making its own products. Being a manufacturer meant Takeda controlled what it sold, and soon it was churning out things like quinine and saccharin, becoming the first in Japan to make the sweetener in 1907.
In 1925, the family business became a modern corporation, Chobei Takeda & Co., Ltd., with real capital behind it. More importantly, it pulled research, manufacturing and marketing under one roof. The name shifted a few times over the following decades, but the structure stuck.
In 1985, Takeda paired up with America's Abbott Laboratories to form TAP Pharmaceuticals, a 50:50 joint venture. The same year, TAP began selling Lupron, a prostate cancer drug. That partnership was Takeda's ticket into the huge U.S. market, and it set the stage for a long, fruitful, and eventually complicated relationship.
In 2008, Takeda made its big move into cancer, announcing it would buy Millennium Pharmaceuticals of Cambridge, Massachusetts, for $8.8 billion. The prize was Velcade, a drug for blood cancers, plus a pipeline of experimental medicines in oncology, inflammation and heart disease. Millennium became Takeda Oncology, giving the company a real foothold in the lucrative U.S. cancer market.
By 2011, Takeda had finished absorbing the Swiss drugmaker Nycomed, which had a strong presence in Europe and developing countries. Overnight, Takeda's reach stretched to more than 70 countries. It was no longer just a Japanese company with a U.S. side project; it was becoming a genuinely global player.
In 2015, Takeda did something radical for a 234-year-old Japanese company: it named Christophe Weber, a foreigner, as president and CEO. The move sent shockwaves through Japan's pharma industry. Weber would go on to lead a sweeping transformation of Takeda over the next decade.
In 2019, Takeda pulled off its biggest gamble yet, buying Shire for roughly $50 billion and rocketing into the global top 10 biopharmas. The deal brought scale, products like Vyvanse and a rare-disease pipeline, and made the U.S. about half of Takeda's revenue. But it also loaded the company with debt and integration headaches, kicking off a long stretch of selling off assets to pay down what it owed.
In 2025, Julie Kim became president and CEO as Christophe Weber retired after twelve years. Kim had joined Takeda through the Shire deal and had run its plasma therapies and U.S. businesses. She laid out growth around two horizons and pointed to three major launches planned for the next year.
By 2026, Takeda had positive late-stage results for three experimental drugs and was filing for approval, preparing to launch them within the year as its next generation of growth drivers. The company is shifting from a maturing portfolio to a new cohort of blockbuster brands while investing in technology and AI. A transformation program is expected to deliver annual savings of more than JPY 200 billion by FY2028 to help fund those launches.
Competitors are the other giants hunting the same patients — Roche, Novartis, Eli Lilly, and AstraZeneca, among others. Takeda's edge is depth in rare diseases and plasma-based medicines, plus a long history in Japan. Its vulnerability is that it is smaller than the very biggest players, carries more debt than many peers, and leans on a few products. It pays a steady dividend and reinvests in research, which is what shareholders mostly expect from a mature drugmaker.
Saved answer · last researched 24 Oct 2026